Ken Griffin Janux Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 5,300 shares of JANX stock, worth $326,268. This represents 0.0% of its overall portfolio holdings.

Number of Shares

5,300

Previous 1,800 194.44%

Holding current value

$326,268

Previous $75,000 220.0%

% of portfolio

0.0%

Previous 0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$35.29 - $50.26 $19.3 Million - $27.5 Million	-547,348 Reduced 35.15%	1,009,768 $45.9 Million
Q2 2024 Aug 14, 2024	SELL	$35.12 - $64.78 $27.9 Million - $51.4 Million	-793,122 Reduced 33.75%	1,557,116 $65.2 Million
Q1 2024 May 15, 2024	SELL	$7.93 - $49.75 $6.11 Million - $38.3 Million	-769,967 Reduced 24.68%	2,350,238 $88.5 Million
Q4 2023 Feb 14, 2024	SELL	$5.85 - $11.7 $1.82 Million - $3.64 Million	-311,004 Reduced 9.06%	3,120,205 $33.5 Million
Q3 2023 Nov 14, 2023	BUY	$9.56 - $14.0 $12.6 Million - $18.4 Million	1,315,635 Added 62.19%	3,431,209 $34.6 Million
Q2 2023 Aug 14, 2023	BUY	$11.08 - $15.92 $2.91 Million - $4.18 Million	262,548 Added 14.17%	2,115,574 $25.1 Million
Q1 2023 May 15, 2023	SELL	$11.25 - $22.21 $20,081 - $39,644	-1,785 Reduced 0.1%	1,853,026 $22.4 Million
Q4 2022 Feb 14, 2023	BUY	$11.1 - $18.26 $17,704 - $29,124	1,595 Added 0.09%	1,854,811 $24.4 Million
Q3 2022 Nov 14, 2022	SELL	$10.82 - $16.84 $2,337 - $3,637	-216 Reduced 0.01%	1,853,216 $25.1 Million

Others Institutions Holding JANX

# of Institutions

166

Shares Held

37.6M

Call Options Held

85.3K

Put Options Held

654K

View Full List

About Janux Therapeutics, Inc.

Ticker JANX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,663,000
Market Cap $2.56B
Description
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...

More about JANX

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account